Surotomycin + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Associated Diarrhea (CDAD)
Conditions
Clostridium Difficile Associated Diarrhea (CDAD)
Trial Timeline
Jul 1, 2009 → Oct 1, 2009
NCT ID
NCT02835118About Surotomycin + Placebo
Surotomycin + Placebo is a phase 1 stage product being developed by Merck for Clostridium Difficile Associated Diarrhea (CDAD). The current trial status is completed. This product is registered under clinical trial identifier NCT02835118. Target conditions include Clostridium Difficile Associated Diarrhea (CDAD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02835118 | Phase 1 | Completed |
| NCT02835105 | Phase 1 | Completed |
Competing Products
20 competing products in Clostridium Difficile Associated Diarrhea (CDAD)